Arvinas (NASDAQ:ARVN) Reaches New 52-Week Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN) shares reached a new 52-week low on Monday . The company traded as low as $16.43 and last traded at $16.26, with a volume of 210125 shares traded. The stock had previously closed at $17.77.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ARVN. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 price target (down from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. Stifel Nicolaus cut their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Finally, Guggenheim reaffirmed a “buy” rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, Arvinas presently has an average rating of “Buy” and an average price target of $60.00.

Arvinas Stock Up 5.5 %

The company has a market cap of $1.21 billion, a PE ratio of -6.38 and a beta of 1.88. The stock’s 50 day simple moving average is $18.41 and its two-hundred day simple moving average is $22.80.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the company earned ($2.53) EPS. Analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Insider Transactions at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ian Taylor sold 9,020 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arvinas

A number of large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Arvinas during the 4th quarter worth approximately $28,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares in the last quarter. KBC Group NV raised its holdings in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP boosted its stake in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Arvinas in the 4th quarter worth about $171,000. 95.19% of the stock is owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.